Page 43 of 110: studies 421 to 430 of 1,096, newest first. Back to the 5-MeO-DMT overview
Neurology June 9, 2026 Emmanuelle A. D. Schindler, Kevin Lenaburg, Robert Wold
To carry out a survey on N,N-dimethyltryptamine (DMT) use in adults with cluster headache.
Zenodo (CERN European Organization for Nuclear Research) June 9, 2026 Emma Dobbin preprint
UPDATED 2026-06-09 Corrected dataset attribution from Timmermann et al. (2019) to Pallavicini et al. (2021) UPDATED 2026-01-21 Background: Psychedelic substances produce profound alterations in conscious experience, yet the neural mechanisms underlying phenomenal richness remain poorly understood. Static measures of neural integration and complexity have shown limited success in predicting...
Drugs June 4, 2026 Kevin F. Boehnke, Niloufar Pouyan, Jacob S. Aday
Chronic pain is common, costly, and for many, remains inadequately treated by existing pharmacologic and non-pharmacologic approaches. In parallel with growing dissatisfaction with conventional therapies, classic serotonergic psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), ayahuasca, N,N-dimethyltryptamine (DMT), and mescaline, administered alone or within...
The Journal of Clinical Psychiatry June 3, 2026 Martin Johnson, Pau Aceves Baldo, Emilio Arbe et al.
Objective: Postpartum depression (PPD) is a debilitating mood disorder with peripartum onset. Current treatment options are limited in PPD. GH001 is a synthetic inhalation formulation of the psychoactive molecule mebufotenin (5-MeO-DMT). This trial investigated the preliminary efficacy and safety of GH001 in adult females with PPD. Methods: This phase 2a, proof-of-concept, open-label trial...
European Psychiatry June 1, 2026 A. M. Matas Ochoa, A. R. Quiroga, I. D. Sacristán
Introduction Psychedelics are hallucinogenic agents that are awakening scientific interest in recent years, especially in the field of mental health. Psychedelics induce non-ordinary states of consciousness and alterations in the emotions and in cognition and could be beneficial in treating some mental illness. Objectives The objective of the poster is to expand knowledge about emerging...
European Psychiatry June 1, 2026 G. Smagin, J. Tripp
Introduction MM120 (lysergide D-tartrate, a formulation of LSD) is under development as a potential treatment for generalized anxiety and major depressive disorders. How psychedelic drugs interact at the TrkB receptor, a key target of neuroplasticity, is not reported. Objectives The study evaluated binding and functional activity of known serotonergic psychedelic compounds and SRI fluoxetine at...
European Psychiatry June 1, 2026 Michał Pastuszak, Katarzyna Jakuszkowiak‐wojten, Maria Gałuszko‐węgielnik et al.
Introduction Research on psychedelic compounds has grown quickly in the past decade. Yet molecule-specific, quantitative summaries are scattered, making it hard to see how interest differs by compound or over time. Objectives To quantify PubMed-indexed publications on ketamine, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), psilocybin, and psilocin; to describe annual trends...
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie June 1, 2026 Francisco Madrid-Gambin, Pablo Mallaroni, Noemí Haro et al.
Ayahuasca is a psychoactive brew containing N,N-dimethyltryptamine (DMT) and β-carboline alkaloids that induces marked alterations in perception, emotion and self-referential processing. However, the multiscale biological organization linking peripheral metabolism, brain network dynamics, neurochemistry, and subjective experience in humans remains poorly understood. Here, we applied an...
bioRxiv : the preprint server for biology June 1, 2026 Panagiotis Fotiadis, Hyunwoo Jang, Rui Dai et al. preprint
Brain waves are ubiquitous phenomena of human brain activity. As they propagate, they coordinate neural communication, shaping conscious perception. Understanding how brain waves unfold across space and time is thus critical for uncovering the neural mechanisms that support and suppress consciousness. Here, we analyzed data from the Human Connectome Project alongside multiple independent human...
Brain and Behavior June 1, 2026 Christopher Poppe, Liisa Lyck, Laura Bechtold et al. 1 citation
Expectations strongly shape participant experiences in clinical trials, contributing to placebo effects that complicate interpretation of outcomes. While quantitative tools exist to measure expectations, their subjective and multidimensional nature, especially for individuals with treatment-resistant depression (TRD), remains underexplored. This study aimed to explore the motivations and...